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Summary
Objectives: Bloodstream infections (BSI) remain a major cause of morbidity and
death in patients undergoing treatment for cancer. However, all recent epidemiolo-
gical and therapeutic studies underline the absolute need for knowledge of the factors
governing the infections in each center. The aim of this study is to identify the factors
affecting BSI in the pediatric service of the National Cancer Institute (NCI) at Cairo
University. More tailored policies for the treatment of patients with febrile neutro-
penia following chemotherapy can then be created.
Patients and methods: Over a 12-month period, all children with cancer and fever,
with or without neutropenia, who were admitted to the NCI for empirical therapy of
febrile episodes and who had a microbiologically confirmed bloodstream infection
were studied retrospectively.
Results: A total of 328 BSI occurred in 1135 febrile episodes in pediatric cancer
patients at the NCI in one year. Gram-positive bacteria were isolated in 168 episodes
(51.2%) and 61.9% of the total isolates (either single or mixed), Gram-negative in 97
(29.6%), and mixed infections in 45 (13.7%). The common causative agents of blood-
stream infections in this study were coagulase-negative staphylococci (16.2%),
Staphylococcus aureus (13.4%), Streptococcus spp. (12.1%) followed by Acinetobacter
spp. (6.7%) and Pseudomonas spp. (5.5%). Fungemia was encountered in 18 episodes,* Corresponding author. Tel.: +202 5724202; fax: +202 3367107.
E-mail address: hadir38@hotmail.com (H. El-Mahallawy).
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being mixed in nine of them. A more serious BSI in terms of a prolonged episode was
encountered in 30.2% of the episodes and was significantly associated with patients
being hospitalized, having intensified chemotherapy, polymicrobial and fungal infec-
tion, lower respiratory tract infections and persistent neutropenia at day seven.
Conclusions: In a large population of children, common clinical and laboratory risk
factors were identified that can help predict more serious BSI. These results encou-
rage the possibility of a more selective management strategy for these children.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Bloodstream infections (BSI) remain a major cause
of morbidity and death in patients undergoing treat-
ment for cancer.1 Cancer patients are predisposed
to BSI for several reasons: Alterations in anatomic barriers, both internal
and external, enhance access of bacteria and
fungi to the bloodstream. Changes in both cell-mediated and humoral
immunity occur related both to the primary tumor
and the subsequent treatment.2 Infectious complications in pediatric hematol-
ogy—oncology patients have been significantly
associated with the presence of indwelling cathe-
ters.3
Although many infections in this immunocompro-
mized population of patients may not be preventa-
ble through infection control measures, the careful
evaluation of specific infection rates permits the
identification of risk factors that may be targeted by
infection control policies.4
There is no doubt that immediate empirical
broad-spectrum anti-microbial therapy is standard
in the management of BSI. However, conventional
clinical and radiological signs of infection may be
either absent or inadequate and this urgent anti-
microbial strategy results in the over-treatment of a
considerable percentage of neutropenic patients.5
Nowadays there is a growing interest in risk strati-
fication of febrile neutropenia in cancer patients.
This is based on predictive models from large studies
in order to apply risk-directed therapy to this popu-
lation and to apply suitable preventive and manage-
ment strategies. Successful attempts have been
made to stratify patients into high risk and low risk
groups and differentiate treatment options.6—8
The aim of this study is therefore to evaluate the
impact of different risk factors contributing to more
serious bloodstream infectious episodes encoun-
tered in the pediatric oncology service. The infor-
mation collected can be used to implement
guidelines for the prevention and management ofBSI at the National Cancer Institute at Cairo Uni-
versity.Patients and methods
Study design
The medical records of pediatric patients who had a
positive blood culture at the pediatric oncology
department at the National Cancer Institute from
January to December 1999 were retrospectively
reviewed.
This center is a 90-bed tertiary care institution
receiving an average of 1000 new cases per year.
Blood cultures were performed on the occurence of
fever in any cancer patient, either newly diagnosed
or under chemotherapy, whether neutropenic or
not.
Definitions
Fever was defined as a single temperature of 38.5 8C
or at least two readings of 38 8C taken two hours
apart; rectal measurements were avoided. Patients
were considered neutropenic if their absolute neu-
trophil count (ANC) at the onset of therapy was
<1  109/L or if it fell below that level in the two
days following the initiation of therapy. The abso-
lute neutrophil count was further categorized
according to whether the expected duration of
neutropenia (<0.5  109/L) extended to more than
seven days. Bloodstream infections included both
bacteremia and fungemia. When the blood culture
revealed a potential contaminant, other clinical
evidence of ongoing BSI (such as rigors, hypotension,
or documented infection at a second site with the
same organism) was required for confirmation of
true infection.
Microbiology
Two blood culture sets from two separate veins were
usually drawn from each patient within the first day
of fever. If the cannula site, portacath, or central
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infection, a blood sample was obtained from each,
in addition to the peripheral vein samples.
Collected blood was injected directly into Bac-
tec1 (Becton Dickinson, USA) culture vials. Vials
were incubated in the Bactec1 9050 incubator after
collection. Identification of isolates was carried out
utilizing Sensititre AP80 and AP90 auto-identifica-
tion plates (AccuMed International Ltd., Imberhorne
Lane, East Grinstead, West Sussex, UK) for Gram-
negative and Gram-positive organisms respectively.
The plates for minimum inhibitory concentration
(MIC) were also supplied by the same company.
For mixed injections the MIC was considered as that
of the predominant organism causing infection.
Clinical data
Retrieved data included patient hospital number (ID
number), age, sex, episode date and number, type
of malignancy, clinical state during episode, and the
protocol of chemotherapy received. Data at the
time of bloodstream infection included the degree
and pattern of fever, absolute neutrophil count
(ANC), empirical antimicrobial therapy, the pre-
sence of possible sites of infection such as oral
mucositis, intravenous catheter site infection, skin
abrasions or cellulitis, urinary tract infections and
lower respiratory tract (RT) infections. Diarrhea was
defined as an abnormal increase in stool liquidity
and more than four bowel movements per day.
Antimicrobial therapy
All febrile neutropenic patients were treated
promptly with empiric intravenous broad-spectrum
antibiotics: a third generation cephalosporin com-
bined with an aminoglycoside. They were given
either ceftazidime 150 mg/kg daily in three divided
doses combined with amikacin 15 mg/kg once daily
or ceftriaxone 100 mg/kg once daily combined with
amikacin.9 If fever persisted for more than 72 hours,
vancomycin (10 mg/kg/dose in four divided doses a
day) was added for those who had severe mucositis,
documented catheter-related infection with site
inflammation, or colonization with resistant Gram-
positive organisms, hypotension or severe sepsis and
for those had been on quinolone prophylaxis.10
Otherwise, the regimen was altered to imipenem
60 mg/kg daily in four divided doses with continua-
tion of amikacin. Empirical intravenous antifungal
therapy (amphotericin B 0.7 mg/kg given once
daily) was added if fever was present on day seven.3
Antibiotic therapy was continued until the patient
became afebrile and neutrophil count exceeded
0.5  109/L.The episode was considered to be successfully
controlled when fever and clinical signs resolved
after 72 hours. Persistence of fever for seven days or
more defined the morbid status of the episode and
the episode was then considered severe. The epi-
sode was considered to be a treatment failure if it
ended with death within amonth of positive culture.
Statistical methods
SPSS software was used for data management. Mul-
tiple episodes of infection in the same patient were
considered as independent events. The first part of
the analysis was descriptive. Outcome variables
were defined as continuous fever if on the seventh
day of admission the condition was still morbid, and
death indicated an end status of the disease. To
make inferential comparisons between the distribu-
tions in the two populations with morbid and non-
morbid conditions as well as in dead and alive
population, the Chi-square test was used for cate-
gorical independent variables and the t-test for
continuous data.
In the second part of the analysis a multivariate
model was fitted to the data by application of a
stepwise backward procedure. Coefficients were
estimated with the maximum likelihood method
and tests based on likelihood ratios to exclude (or
to re-enter) variables in the model. For the final
model, odds ratio with 95% confidence intervals was
calculated. All of the significance probabilities pro-
vided are two-tailed.Results
Patient characteristics
Of 3687 admissions to the pediatric inpatient service
from January to December 1999, a total of 1135
febrile episodes occurred. From the latter figure,
328 were bloodstream infections that were identi-
fied in 250 patients and constituted 29% of the total
febrile episodes. The patients ranged in age from
two weeks to 18 years with a median of six years.
Fifty-nine percent of them were male and 41%
female. The original diagnoses of patients were
acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), lymphomas and solid tumors in
36.6%, 22.3%, 14.9% and 26.2% of cases respectively.
Collectively, 242 of the episodes occurred in
patients with hematological malignancies, whereas
solid tumors were the underlying disease in 86
episodes. 41.3% of febrile episodes occurred during
maintenance or complete remission, 37.6% during
relapse, 14.7% during the induction phase and 6.4%
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chemotherapy were given during 83 (25.3%) of the
episodes and standard protocols were given in 219
(66.8%), while in 26 (7.9%) of episodes, patients
were not under chemotherapy.
Bloodstream infections occurred once in 197
(78.8%) patients and twice or more in 53 (21.2%)
of them. Patients were hospitalized in 37.5% of the
episodes (n = 123). Gram-negative organisms were
encountered more frequently in hospitalized
patients than in outpatients (45.2% vs. 32.0%),
whereas Gram-positive organisms were isolated less
frequently in inpatients than in outpatients (54.8%
vs. 68%), p = 0.03. Infection with more than one
organism was also more common in hospitalizedTable 1 Causative organisms in 328 bloodstream infection
Institute, Cairo University, during the year 1999.
General Species
Gram-positive cocci
Staphylococcus aureus
Coagulase-negative stap
Streptococcus spp.
Enterococcus spp.
Microococcus spp.
Aerococcus viridans
Other
Gram-negative bacilli
Pseudomonas spp.
Acinetobacter spp.
Enterobacter spp.
E. coli
Pasteurella spp.
Klebsiella spp.
Other
Fungi
Aspergillus fumigatus
Candida tropicalis
Candida parapsilosis
Candida krusei
Gram-positive bacilli
Bacillus ceieus
Colynebacterium spp.
Listeria spp.
Mixed isolates
Fungi and Gram +ve coc
Fungi and Gram ve or
Mix of Gram +ve cocci
Gram +ve cocci and v
Gram +ve cocci and +ve
Gram ve and +ve baci
Other
Total
Gram +ve: Gram-positive organisms; Gram ve: Gram-negative orgthan outpatients (20.3% vs. 9.8%), p = 0.007. Persis-
tent fever, persistent neutropenia (ANC below
0.5  109/L) and a poor outcome were reported
more frequently in hospitalized than non-hospita-
lized patients, p < 0.001; (45.5% vs. 21%), (72.8% vs.
45.5%) and (28.5% vs. 7.8%), respectively.
Clinical features
Either a potential focus of infection (such as mild
mucositis and mild skin cellulitis) or a documented
focus of infection was encountered in 277 (84.5%) of
the 328 bloodstream episodes, whereas 15.5% of
episodes lacked a focus. Upper respiratory tract
infections were reported in 151 (46%) of thes in the pediatric oncology unit at the National Cancer
Number Percent
168 51.2
44 13.4
hylococci 53 16.2
40 12.1
13 4.0
5 1.5
4 1.2
9 2.7
97 29.6
18 5.5
22 6.7
9 2.7
7 2.1
6 1.8
5 1.5
30 9.2
9 2.7
4 1.2
3 0.9
1 0.3
1 0.3
3 0.9
1 0.3
1 0.3
1 0.3
45 13.7
ci 12 3.7
ganisms 9 2.7
7 2.1
e organisms 15 4.6
bacilli 1 0.3
lli 1 0.3
6 1.8
328 100.0
anisms.
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Figure 1 The in-vitro antibiotic susceptibility (%) of
Gram-positive (n = 168) and Gram-negative bacteria
(n = 97) isolated from blood cultures of pediatric cancer
patients with BSI during one year at National Cancer
Institute, Cairo University. Ak: amikacin, A/S: ampicillin/
sulbactam, P/T: piperacillin/tazobactam, Cz: ceftazi-
dime, Ip: imipenem, Cp: cefepime, Cefo: cefoperazone,
Cip: ciprofloxacin, and Vanc: vancomycin.
Table 2 Risk factors attributed to the persistence of
fever on day seven.
Febrile Afebrile p-value*
N = 99 N = 229
No. % No. %
Disease type
Hematological 84 84.8 158 69.0 0.003
Solid tumor 15 15.2 71 31.0
Chemotherapy
None 7 7.1 19 8.3 <0.001
Standard 52 52.5 157 72.9
Intensive 40 40.4 43 18.8
Focus of infection
Mucositis 51 51.5 100 43.7 0.19
Skin infection 17 17.2 32 14.0 0.46
Catheter-related 16 16.2 29 12.7 0.39
Lower respiratory
tract
59 59.6 68 29.7 <0.001
Bacteremia
Gram +ve 36 54.5 132 66.3 0.09
Gram ve 30 45.5 67 33.7
Single isolate 69 69.7 214 93.4 <0.001
Polymicrobial 30 30.3 15 6.6
Fungemia 13 13.1 5 2.2 <0.001
Neutrophils
Day 7 neutrophil
count <0.5 
109/L (n = 170)
71 77.2 99 45.4 <0.001
Day 7 neutrophil
count 0.5 
109/L (n = 140)
21 22.8 119 54.6
Outcome of episode
Death 31 31.3 20 8.7 <0.001
Survival 68 68.7 209 91.3
* p-value is significant at 0.05 level; Gram +ve: Gram-
positive organisms; Gram ve: Gram-negative organisms.episodes; mucositis being the most frequent site.
Lower respiratory tract infections were recorded in
127 (38.7%) of the occurrences. Gastroenteritis
manifested by diarrhea, with or without vomiting,
and abdominal pain was present at the time of BSI in
67 (20.4%) episodes. Other sites of infection
included the skin (perianal cellulitis or ulcers, facial
cellulitis, skin abscesses, infected bed sores and
others) and catheter-related infections and were
found in 49 (14.9%) and 45 (13.7%) episodes respec-
tively. Urinary tract infections were recorded least
often, in six (1.8%) patients.
Neutrophils and fever
At the onset of febrile episodes, ANC was below
1.0  109/L in 287 (87.5%) episodes and in 77.2% the
count was <0.5  109/L. At day four and day seven
of evaluation, 68.3% and 54.8%, respectively, of
episodes were associated with ANC below 0.5 
109/L. Persistent fever at day four was encountered
in 53% (n = 174) and after a week in 30.25% (n = 99).
Fever at day seven was not found to be related to
neutropenia at the onset of fever (p = 0.92) whereas
it was significantly related to reduced ANC
(<0.5  109/L) at day four (p = 0.001) and day seven
(p = 0.001).
Microbiologic pattern
As a single isolate, Gram-positive cocci were the
most frequently observed cause of BSI, accounting
for 168 (51.2%) of the total number of BSI. Gram-
negative organisms accounted for 97 (29.6%) of the
total number of BSI. Mixed infections were detectedin 45 of the episodes (13.7%); micro-organisms iso-
lated were 35 Gram-positive cocci, 25 Gram-nega-
tive bacilli, 21 fungal isolates and two Gram-positive
bacilli. Fungi constituted 30 of the isolates and were
obtained from a localized site in 12 patients (i.e.
catheter site sample) and from a peripheral blood
sample (fungemia) in 18 patients. Results of the
etiologic agents of the 328 episodes of BSI are
summarized in Table 1 and results of antibiotic
sensitivity for Gram-positive, Gram-negative and
mixed organisms are illustrated in Figure 1. Methi-
cillin-resistant Staphylococcus aureus accounted for
41.7% (18 out of 44) S. aureus isolates. Forty of the
organisms isolated as causes of bacteremia were
resistant to all used antibiotics, but this multi-resis-
tance was not significantly associated with persis-
tence of fever at day seven, nor with an unfavorable
outcome, p = 0.28 and 0.20 respectively.
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Table 3 Outcome of bloodstream infections in relation to different risk factors studied.
Favorable (survival) Unfavorable (death) p-value*
N = 277 N = 51
No. % No. %
Disease type
Hematologic 199 71.8 43 84.3 0.063
Solid tumor 78 28.2 8 15.7
State during episode
Complete remission 120 46.9 5 10.4 <0.001
Relapse 87 34.0 27 56.3
New/induction 49 19.1 16 33.3
Chemotherapy
None 19 6.9 7 13.7 0.03
Standard 193 69.7 26 51.0
Intensive 65 23.5 18 35.3
Focus of infection
Mucositis 129 46.6 22 43.1 0.65
Skin infection 39 14.1 10 19.6 0.31
Catheter-related 37 13.4 8 15.7 0.66
Lower respiratory tract 94 33.9 33 64.7 <0.001
Bacteremia
Polymicrobial 20 7.2 25 49.0 <0.001
Gram +ve 157 65.1 11 45.8 0.06
Gram ve 84 34.9 13 54.2
Fungemia 5 1.8 13. 25.5 <0.001
Neutrophils
Day 7 neutrophil count
<0.5  109/L (n = 170)
138 52.5 32 68.1 0.05
Day 7 neutrophil count
0.5  109/L (n = 140)
125 47.5 15 31.9
* p-value is significant at 0.05 level; Gram +ve: Gram-positive organisms; Gram ve: Gram-negative organisms.Response to empirical therapy
The majority of the episodes (n = 208, 63.4%)
responded to first-line empirical antibiotic therapy.
The two regimens used as first-line empirical anti-
biotic therapy did not show significant differences
with respect to the persistence of fever or the
outcome, p = 0.30 and 0.46 respectively.Table 4 Stepwise logistic regression results of the variable
day seven.
Variables B S.E.
Hospitalization 0.762 0.309
Intensive chemotherapy 1.148 0.304
Polymicrobial episode 2.030 0.426
Lower RT infection 1.449 0.313
Neutrophils at Day 7 >0.5  109 K 1.002 0.330
Constant 3.211 0.540
OR: the odds of persistence of fever on day seven.Morbidity and mortality
Age and gender were not found to be contributors to
either morbidity or mortality. Factors related to
morbidity and mortality are listed in Tables 2 and
3 respectively. In 37/51 (72.5%) deaths occurring in
the 328 infectious episodes, BSI was judged to have
either contributed to or caused the terminal events that significantly correlated to persistence of fever on
p-value Odds ratio (OR) 95% C.I. for (OR)
Lower Upper
0.014 2.142 1.170 3.921
<0.001 3.153 1.737 5.725
<0.001 7.614 3.307 17.532
<0.001 4.261 2.307 7.869
0.002 0.367 0.192 0.701
<0.001 0.040
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Table 5 Stepwise logistic regression results of the variables that significantly correlated to an unfavorable outcome
of bloodstream infections.
Variables B S.E. p-value Odds ratio (OR) 95% C.I. for (OR)
Lower Upper
Hospitalization 1.208 0.450 0.007 3.346 1.386 8.075
Disease in remission
(Relapsed) 1.505 0.618 0.015 4.502 1.340 15.126
(Induction) 1.953 0.650 0.003 7.048 1.972 25.193
Polymicrobial episode 2.447 0.542 0.000 11.556 3.996 33.420
Lower RT infection 1.094 0.445 0.014 2.987 1.249 7.144
Fungemia 1.537 0.801 0.055 4.649 0.967 22.353
Constant 4.930 0.649 0.000 0.007
OR: the odds of death.through septicemia. The other causes of death were
relapsing or resistant malignant disease (n = 11),
intra-cranial hemorrhage (n = 2) and disseminated
intravascular coagulation (n = 1). Although Gram-
negative bacteremia was observed more frequently
among patients with continuous fever and in
deceased patients than Gram-positive bacteremia,
the differences were not statistically significant.
Multivariate analysis
The co-morbid conditions found after multivariate
analysis correlated to persistence of fever after the
first week are shown in Table 4. Odds ratio or risk of
death along with its confidence intervals for the
presence of these risk factors are shown in Table 5.Discussion
Infection is an expected sequel after the newer
chemotherapeutic regimens for childhood cancer.2
With the ongoing use of dose-intensive regimens and
the widespread use of indwelling catheters, inves-
tigation of the infectious complications of cancer
continues to be an important area of clinical
research. The identification of clinical or laboratory
predictors of causes of morbidity and mortality in
febrile patients with cancer is crucial to early treat-
ment.11 It was previously reported that an organism
was isolated in 10—20% of pediatric cancer patients
with febrile neutropenia.2 Elting and his colleagues
have reported an overall rate of bacteremia of 22%
from the results of several European studies in
febrile neutropenic pediatric oncology patients.12
In a single pediatric oncology unit, bacteremia was
reported in 35.4% of febrile neutropenic episodes
over a five-year period.13 In the present study BSI
accounted for 328 of 1135 febrile episodes occurring
in 250 patients and constituted 29% of total febrileepisodes over a one-year period. This prevalence is
comparable to other series.
Trends in the bacterial isolates found in cancer
patients have varied over the past few decades. The
results of this study are consistent with the changing
epidemiology of infections in patients with neutro-
penia and cancer towards a predominance of Gram-
positive organism predominance.3 As was documen-
ted in the studies of the International Antimicrobial
Therapy Cooperative Group of the European Organi-
zation for Research and Treatment of Cancer
(EORTC), there has been a clear shift in infecting
organisms causing BSI, so that now60—70% of BSIwith
a single organism are due to Gram-positive cocci.14 It
was previously demonstrated that Gram-positive
cocci were the predominant cause of BSI in pediatric
cancer patients at the National Cancer Institute at
Cairo University, constituting 68.9% of organisms iso-
lated over a six-month study period.15 In the present
study, over a longer period,Gram-positive cocciwere
found toaccount for61.9%of thetotal isolates (either
single or mixed with other isolates) and 51% of the
single isolates caused BSI. This drop between the two
studies could be explained by the increase in mixed
and fungal infections compared to that previously
recorded at the National Cancer Institute. This is
most probably due to the use of more intensified
chemotherapeutic protocols used in the manage-
ment of pediatric cancer patients and also due to
better detection after using the Bactec1 system.
The most common single causative agents of
bloodstream infections in this study were coagu-
lase-negative staphylococci (16.2%), Staphylococ-
cus aureus (13.4%), Streptococcus spp. (12.1%)
followed by Acinetobacter spp. (6.7%) and Pseudo-
monas spp. (5.5%). 13.7% of the episodes were
polymicrobial. Similar trends have been documen-
ted in other studies. Of the 399 episodes of BSI
occurring among 273 patients with neutropenia in
a one-year study, Gram-positive organisms were
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161 (40%) and Candida spp. in 17 (5%). Overall, the
common pathogens isolated were S. aureus (18%),
coagulase-negative staphylococci (16%), Klebsiella
spp. (10%), E. coli (10%), Enterococcus spp. (8%) and
Pseudomonas spp. (6%).16
In a multi-center study, carried out to determine
the causative agents of bacteremia in children with
cancer, the most frequently isolated pathogens
were coagulase-negative staphylococci (43%), S.
aureus (16%), E. coli (9%), Klebsiella spp. (8%),
Pseudomonas spp. (5%) and Candida spp. (4%).17
In another multi-center surveillance study con-
ducted in 18 pediatric hematology centers over a
one-year period, Gram-positive cocci caused 45%
(85/191) of the episodes, Gram-negative rods 41%
(78/191) and fungi 9%; whereas 5% of the episodes
were polymicrobial infections.18
In the present study, risk factors contributing to a
more serious bloodstream infection were prolonged
neutropenia (i.e. ANC 0.5  109/L at day four and
seven) rather than ANC at the onset of fever, hema-
tological malignancies, hospitalization at time of
diagnosis of febrile episode, intensified protocols
of chemotherapy and lower respiratory tract infec-
tion as a co-morbid condition.
This study related morbidity (due to infection) to
persistent fever, whether continuous or intermit-
tent, at day seven. Fever at day seven was reported
in 99 (30.2%) of the BSI episodes; while an unfavor-
able outcome was reported in 15.5% (51/328). In a
multi-center surveillance study, the overall mortal-
ity rate from any cause within 30 days of the first
positive blood culture was 11% and was higher
among patients who were neutropenic at the onset
of infection than among those who were not neu-
tropenic (15 vs. 4%, p = 0.03). In addition, the mor-
tality was significantly higher among fungemia and
polymicrobial infections than in single Gram-posi-
tive or Gram-negative bacteremia.18 In this study,
polymicrobial infections were significantly asso-
ciated with a higher mortality rate.
In a study carried out to investigate the etiologic
organisms, risk factors and other infectious features
of septic shock in hematology oncology patients
with neutropenic fever, Gram-negatives were iso-
lated significantly more frequently than Gram-posi-
tive bacteria — they accounted for 78.3% of isolates
in 39 patients with septic shock, p  0.001.19 On
multivariate analysis, leukocyte count at the onset
of fever was the only significant risk factor for septic
shock in febrile neutropenic cancer patients.19
Furthermore, Alexander and coworkers found that
febrile neutropenia in children with cancer with an
anticipated duration of neutropenia of over seven
days, with or without a significant co-morbidity,showed a significantly higher frequency of bacter-
emia, other documented infections and serious
medical complications than those with a shorter
duration of neutropenia (41% versus 4%).6 On the
other hand, febrile children with lower risk neutro-
penia (i.e. expected duration of neutropenia less
than a week), were found to survive pass their
febrile episodes with no major complications or
death.8 Rapid neutrophil recovery was associated
with good prognosis in 762 consecutive episodes of
febrile neutropenia over a five-year period in a
single pediatric oncology unit.13
Immunocompromized febrile cancer patients are
often characterized by the lack of an evident focus
of infection accompanying BSI, perhaps because of
the inability to mount an adequate inflammatory
response.2 Nonetheless, a potential or documented
focus of infection frequently accompanied BSI in this
study.
Upper respiratory tract infection, mainly muco-
sitis, was the most common documented site of
infection in our patients (46.0%), followed by lower
respiratory tract infections (38.7%), diarrhea
(20.4%) and then catheter-related infections
(13.7%). A significant association of RT infections
with BSI has previously been observed. Paganini and
his coworkers found clinical evidence of infection in
47% of episodes of pediatric febrile neutropenia
during anticancer therapy; the most common site
was the upper RT in 81%.8 In another study, a
correlation between BSI and the presence of an
indwelling catheter was found in 20% (23/114) of
episodes among neutropenic cancer patients.18 In
the present study, lower RT infection proved to be a
co-morbid condition and was significantly asso-
ciated with a prolonged course of the BSI episode
and an unfavorable outcome. In agreement with the
findings here, the most common infection sites in a
two-year study in hematology oncology patients
with neutropenic fever were the respiratory and
gastro-intestinal tracts. Respiratory tract infection
was significantly more frequent in patients who
developed septic shock, p = 0.038.19
Resistance patterns of pathogens isolated from
febrile neutropenic patients have emerged as a
significant challenge. It is clear from data presented
in Figure 1 that pathogens causing bacteremia in
pediatric cancer patients at this institution show
high resistance rates to many antimicrobial agents.
Methicillin-resistant S. aureus accounted for 41.7%
of staphylococcal isolates. In a similar study, a sig-
nificant increase in Gram-positive antibiotic resis-
tance was noted: 55% of coagulase-negative
staphylococci were resistant to methicillin, 44% of
S. aureuswere resistant and the resistance of Strep-
tococcus spp. to penicillin reached 50%.17
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reported for Gram-negative pathogens, reaching
60% for ceftazidime, 50% for amikacin and imipenem
and 40% for piperacillin-tazobactam, cefoperazone,
cefepime and ciprofloxacin. The most probable
explanation for these findings is the increased use
of antibiotics in the hospital, as evidenced by amore
profound resistance to both amikacin and ceftazi-
dime, which have been used extensively as first-line
empirical therapy. Fortunately, this pattern of high
resistance was not significantly associated with
either the persistence of fever at day seven or
the outcome. Likewise, the antibiotic regimen used
in this study did not significantly affect either the
persistence of fever or the outcome. The discre-
pancy between in vitro susceptibility and clinical
response suggests that, in the neutropenic patient,
outcome is a function of a combination of the host
and microbial factors. However, the high antibiotic
resistance rates encountered necessitate the inves-
tigation of a link between antimicrobial prescribing
behavior and antimicrobial resistance.
From the results of this study, factors can be
identified that may serve as determinants for more
serious bloodstream infections in pediatric oncology
patients. These include: hospitalization at the time
of diagnosis of the febrile episode, intensified che-
motherapeutic protocols, prolonged neutropenia,
lower respiratory tract infections and multiple
coexisting organisms. The same criteria can be used
as prognostic features of the outcome of blood-
stream infections with the addition of fungemia
and state of underlying disease, as uncontrolled
cancer and the induction phase of acute leukemia
were found to be more hazardous.
Further researchat theNational Cancer Institute is
needed to evaluate empirical antibiotic regimens
using these risk criteria. In addition, better surveil-
lance of antimicrobial prescribing practice is neces-
sary to control the high rates of antibiotic resistance.
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